Simulations Plus, Inc. (NASDAQ:SLP) Short Interest Update

Key Points

• Simulations Plus, Inc. experienced a 29.5% decline in short interest in September, dropping from 1,660,000 to 1,170,000 shares, representing 7.2% of its total shares.
• Wall Street analysts have given Simulations Plus an average rating of "Hold", with forecasts ranging from a target price of $20.00 to $28.00.
• Institutional ownership is strong, with 78.08% of shares held by institutional investors, indicating significant confidence in the company's growth prospects.

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 1,170,000 shares, a decline of 29.5% from the September 15th total of 1,660,000 shares. Based on an average trading volume of 689,700 shares, the short-interest ratio is presently 1.7 days. Currently, 7.2% of the shares of the company are sold short. Currently, 7.2% of the shares of the company are sold short. Based on an average trading volume of 689,700 shares, the short-interest ratio is presently 1.7 days.

Wall Street Analysts Forecast Growth

SLP has been the topic of several analyst reports. Cowen initiated coverage on Simulations Plus in a research note on Tuesday, September 30th. They issued a "hold" rating on the stock. Zacks Research upgraded Simulations Plus to a "hold" rating in a research note on Tuesday, August 12th. Stephens reduced their target price on Simulations Plus from $28.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, July 15th. KeyCorp downgraded Simulations Plus from an "overweight" rating to a "sector weight" rating in a report on Tuesday, July 15th. Finally, William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a report on Tuesday, July 15th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Simulations Plus currently has an average rating of "Hold" and a consensus target price of $24.40.

Institutional Investors Weigh In On Simulations Plus

Several hedge funds have recently bought and sold shares of SLP. First Light Asset Management LLC acquired a new stake in Simulations Plus in the 2nd quarter valued at about $6,232,000. Stephens Investment Management Group LLC acquired a new stake in Simulations Plus in the 2nd quarter valued at about $4,687,000. Ameriprise Financial Inc. lifted its stake in Simulations Plus by 25.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company's stock valued at $15,277,000 after purchasing an additional 176,747 shares during the last quarter. North Star Investment Management Corp. lifted its stake in Simulations Plus by 195.6% in the 3rd quarter. North Star Investment Management Corp. now owns 168,130 shares of the technology company's stock valued at $2,534,000 after purchasing an additional 111,255 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in Simulations Plus by 435.9% in the 2nd quarter. Marshall Wace LLP now owns 133,278 shares of the technology company's stock valued at $2,326,000 after purchasing an additional 108,407 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Stock Up 2.1%

SLP stock opened at $18.00 on Thursday. The business's fifty day moving average is $14.96 and its 200-day moving average is $20.63. The company has a market cap of $362.24 million, a P/E ratio of -5.71 and a beta of 0.99. Simulations Plus has a twelve month low of $12.39 and a twelve month high of $37.67.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.